Clene Inc., a clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, will participate in the upcoming Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada. The conference, organized by JonesTrading with marketing support from B2i Digital, Inc., is designed to facilitate meaningful interactions between innovative companies and institutional investors through one-on-one meetings, fireside chats, panels, and networking opportunities. Rob Etherington, CEO and President of Clene, emphasized the importance of this event for sharing the company's progress and connecting directly with investors, providing a critical platform to discuss innovative approaches to treating conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis.
The conference will feature notable keynote speakers, including Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization, alongside activities like a Golf Event and Cocktail Reception. Clene's participation underscores its commitment to advancing neurological disease treatment through its investigational therapy CNM-Au8®, which focuses on improving mitochondrial health and protecting neuronal function. This event represents a significant opportunity for Clene to showcase its scientific advancements and engage with potential investors interested in groundbreaking medical research, as detailed in the conference overview available at https://www.jonestrading.com/conferences. The company's focus on neurodegenerative diseases, which affect millions globally, highlights the broader implications of its work for improving patient outcomes and addressing unmet medical needs.
By participating in such high-profile conferences, Clene aims to foster investor interest and support for its clinical programs, which could accelerate the development of therapies for debilitating conditions. The Jones Las Vegas Technology and Innovation Conference serves as a strategic venue for biopharmaceutical companies like Clene to demonstrate their research progress and potential impact on healthcare. For more information on Clene's therapeutic approaches, visit https://www.clene.com. This engagement is crucial as it aligns with the growing demand for innovative treatments in neurology, where advancements can lead to significant improvements in quality of life for patients. The conference's focus on technology and innovation further emphasizes the role of cutting-edge science in driving medical breakthroughs, making Clene's presence there a key step in its mission to transform neurodegenerative disease care.
